Dikkat eksikliği hiperaktivite bozukluğu olan bir ergende modifiye salımlı metilfenidat kaynaklı Raynaud fenomeni-Reference-Cited by-同舟云学术

Dikkat eksikliği hiperaktivite bozukluğu olan bir ergende modifiye salımlı metilfenidat kaynaklı Raynaud fenomeni

Published:2022-09-30 Issue:3 Volume:47 Page:1381-1383
ISSN:2602-3032
Container-title:Cukurova Medical Journal
language:tr
Short-container-title:Cukurova Med J

Author:

GÜLCÜ ÜSTÜN Nur Seda¹,KARAYAĞMURLU Ali²

Affiliation:

1. İSTANBUL ÜNİVERSİTESİ, İSTANBUL TIP FAKÜLTESİ, İSTANBUL TIP PR.

2. ISTANBUL UNIVERSITY, İSTANBUL FACULTY OF MEDICINE, İSTANBUL MEDICINE PR.

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder commencing before the age of 12 years and characterized by developmentally inappropriate inattention, hyperactivity, and/or impulsivity symptoms. Stimulants such as methylphenidate (MPH) are used as first-line therapy for children with ADHD. Psychostimulants may be associated with vascular problems. Raynaud’s phenomenon (RP) is a peripheral vasculopathy potentially associated with connective tissue diseases characterized by recurring reversible vasospasm attacks triggered by cold and emotional stress. Several cases have been published involving RP observed with MPH. The present report discusses a 14-year-old girl with ADHD who experienced RP with the addition of 10 mg modified-release MPH during 27 mg osmotic release (OROS)-MPH therapy, but not during 36 mg OROS-MPH therapy.

Publisher

Cukurova Medical Journal

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference21 articles.

1. REFERENCES 1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.

2. 2. Ercan ES, Polanczyk G, Akyol Ardıc U, Yuce D, Karacetın G, Tufan AE, Tekden M. (2019). The prevalence of childhood psychopathology in Turkey: a cross-sectional multicenter nationwide study (EPICPAT-T). Nordic journal of psychiatry, 73(2), 132-140.

3. 3. Golmirzaei J, Mahboobi H, Yazdanparast M, Mushtaq G, A Kamal M, Hamzei E. (2016). Psychopharmacology of attention-deficit hyperactivity disorder: effects and side effects. Current pharmaceutical design, 22(5), 590-594.

4. 4. de Sousa ADF, Coimbra IM, Castanho JM, Polanczyk GV, Rohde LA. (2020). EXTERNALIZING DISORDERS.Chapter D.1:1-28.

5. 5. Cantu C, Arauz A, Murillo Bonilla LM, López M, Barinagarrementeria F. Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. Stroke. 2003;34(7):1667–72.